Anti-HER2 [4D5]

Absolute Antibody

Anti-HER2 [4D5]

9

The original antibody is directed against the extracellular domain of p185HER2. This antibody does not cross-react with the human EGF receptor (HER1).

The antibody immunoprecipitated p185HER2 from NIH3T3 cells. The binding of the antibody to human tumor cell lines was investigated by fluorescence-activated cell sorting. Increased in cellular fluorescence observed with SK-BR-3 breast adenocarcinoma cells and squamous carcinoma cell line A431, where the binding of the antibody correlated with the levels of p185HER2 expressed by these two cell lines. The antibody inhibited cellular proliferation of SK-BR-3 overexpressing p185HER2 by 56%. The antibody significantly affected the growth of the cell lines MDA-MB-361 and MDA-MB-175-VII, which also express high levels of p185HER2. Further, the antibody completely prevented colony formation by these cells in soft agar. Furthermore, resistance to the cytotoxic effect of tumor necrosis factor alpha is significantly reduced in the presence of this antibody (Hudziak et al., 1989; PMID: 2566907). The humanized IgG1 version of the antibody was constructed and it bound the p185HER2 antigen with higher affinity compared to its parent antibody, it had a similar potency in blocking SK-BR-3 cell proliferation and it supported antibody-dependent cellular cytotoxicity against SK-BR-3 cells (Carter et al., 1992; PMID: 1350088). The structure of the humanized Fab and Fv fragments of the antibody were determined (Eigenbrot et al., 1993; PMID: 8095303). The humanized version of the antibody, trastuzumab, was found to inhibit the growth of human cancer cells and tumor xenografts overexpressing HER2 (Albanell et al., 1999; PMID: 12973420). The Fc silent version of the original antibody was used for mouse tumor growth assays (Campbell et al., 2022; PMID: 35108526). The humanized version of the antibody was used for detection of p185HER-2 expressed on SKBR3 or T6-17 cells by flow cytometry. The antibody was used for immunoprecipitation from T6-17 and B104-1-1 cells (Zhang et al., 1999; PMID: 10493889).

Flow Cytometry, ImmunoPrecipitation, Neutralisation/Blocking, Other Application

Research Use Only

Monoclonal

4D5

ERBB2

erb-b2 receptor tyrosine kinase 2

CD340; c-erb B2/neu protein; HER2; HER-2; HER-2/neu; herstatin; human epidermal growth factor receptor 2; metastatic lymph node gene 19 protein; MLN 19; NEU; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; proto-oncogene c-ErbB-2; proto-oncogene Neu; receptor tyrosine-protein kinase erbB-2; TKR1; tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; VSCN2

Mouse

IgG1

Receptor tyrosine-protein kinase erbB-2

This reformatted mouse IgG1 D265A antibody was made using the variable domain sequences of the original mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

12352203